article thumbnail

RCE Technologies, Inc. Announces First-In-Human Transdermal Continuous Cardiac Biomarker Monitoring

DAIC

RCE) is an innovative artificial intelligence (AI) based medical technology company dedicated to early heart attack detection. RCE) is an innovative artificial intelligence (AI) based medical technology company dedicated to early heart attack detection. This is an innovative platform for measuring biomarkers,” stated Dr. Karlsberg.

article thumbnail

Cardiac cells and mesenchymal stem cells derived extracellular vesicles: a potential therapeutic strategy for myocardial infarction

Frontiers in Cardiovascular Medicine

The content of EVs can also indicate the status of their parental cells and serve as a biomarker for monitoring the risk of cardiac injury. Examining these vesicles can offer fresh perspectives on the development of MI and assist in creating innovative treatments.

article thumbnail

Roche's Lp(a) Gen.2 Molarity Assay Receives FDA Clearance

DAIC

Roche has an unrivaled ability to provide access to testing at scale and is committed to advancing innovation in preventive cardiology.

article thumbnail

The Cardiometabolic Event of the Year: What to Expect at the 19th Annual Cardiometabolic Health Congress (CMHC) 

Cardiometabolic Health Congress

This fall, we come together for the largest and most innovative cardiometabolic event in honor of the legacy of Dr. George L. Innovations in Cardiorenal Metabolic Medicine The event will focus on the whole spectrum of cardiorenal metabolic disease, including obesity, diabetes, lipids, hypertension, and cardiorenal disease.

Education 100
article thumbnail

Crizanlizumab for retinal vasculopathy with cerebral leukoencephalopathy in a phase II clinical study

Journal of Clinical Investigation - Cardiology

These results show promising potential for examining crizanlizumab in larger studies of RVCL-S and similar small-vessel diseases and for using the retina as a biomarker for systemic disease.Trial registration ClinicalTrials.gov NCT04611880.FUNDING FUNDING The Clayco Foundation; DeNardo Education and Research Foundation Grant; Jeffrey T.

article thumbnail

Inhaled NO at a crossroads in cardiac surgery: current need to improve mechanistic understanding, clinical trial design and scientific evidence

Frontiers in Cardiovascular Medicine

The authors will elaborate on how the optimization of inhaled NO therapy, the development of biomarkers to identify the target population and the definition of response can improve the design of future large clinical trials.

article thumbnail

FDA Approves Digital Health Solution for Heart Failure Management

DAIC

This achievement marks a significant milestone for Astellas as we integrate innovative technology with tailored patient support.” “The Digitiva is comprised of three components: the CORE 500 Digital Stethoscope developed by Eko Health Inc., a smartphone app designed for heart failure patients and built on the Welldoc, Inc.